Cylex Inc.

Cylex is a venture-backed, global life sciences company that develops and manufactures in vitro diagnostic products intended to illuminate immunity.  Cylex’s current commercial focus is the Solid Organ Transplant Market.  Our patented technology provides an innovative platform allowing clinicians to simply and reproducibly assess immune cell function.  ImmuKnow®, our first commercial product, is an FDA-cleared noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI).  When used in conjunction with routine monitoring tests, ImmuKnow assay results help guide clinicians in 18 countries with therapy decisions to optimize immunosuppression in transplant patients.